Acyclovir for Immunocompromised Patients with Herpes Zoster

Ervin Epstein; Jordan B. Glaser; Stephen J. Seligman; Joseph Sack; Uri Martinowitz; Yoram Neuman; Jossi Laks; Daniel Katznelson; Bracha Ramot; Henry H. Balfour; Bonnie Bean; Oscar L. Laskin; Richard F. Ambinder; Joel D. Meyers; James C. Wade; John A. Zaia; Dorothee Aeppli; L. Edward Kirk; Anthony C. Segreti; Ronald E. Keeney

doi:10.1056/NEJM198311173092016

Acyclovir for Immunocompromised Patients with Herpes Zoster

Ervin Epstein, Jordan B. Glaser, Stephen J. Seligman, Joseph Sack, Uri Martinowitz, Yoram Neuman, Jossi Laks, Daniel Katznelson, Bracha Ramot, Henry H. Balfour, Bonnie Bean, Oscar L. Laskin, Richard F. Ambinder, Joel D. Meyers, James C. Wade, John A. Zaia, Dorothee Aeppli, L. Edward Kirk, Anthony C. Segreti, Ronald E. Keeney

Laboratory Medicine and Pathology

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Abstract

To the Editor: The important article by Balfour et al. offers convincing evidence of the value of acyclovir in the management of immunosuppressed patients with herpes zoster (June 16 issue).¹ This is a serious and frequently fatal illness. On the other hand, it must not be forgotten that in the usual outpatient practice, where most examples of zoster are encountered, it is not a life-threatening illness. Its importance lies in the discomfort it produces and the possibility of the development of postzoster neuralgia. Therefore, the goals of therapy in this group of patients are different from those considered by Balfour.

Original language	English (US)
Pages (from-to)	1254-1255
Number of pages	2
Journal	New England Journal of Medicine
Volume	309
Issue number	20
DOIs	https://doi.org/10.1056/NEJM198311173092016
State	Published - Nov 17 1983

Access

10.1056/NEJM198311173092016

OpenUrl availability

Full text

Cite this

Epstein, E., Glaser, J. B., Seligman, S. J., Sack, J., Martinowitz, U., Neuman, Y., Laks, J., Katznelson, D., Ramot, B., Balfour, H. H., Bean, B., Laskin, O. L., Ambinder, R. F., Meyers, J. D., Wade, J. C., Zaia, J. A., Aeppli, D., Kirk, L. E., Segreti, A. C., & Keeney, R. E. (1983). Acyclovir for Immunocompromised Patients with Herpes Zoster. New England Journal of Medicine, 309(20), 1254-1255. https://doi.org/10.1056/NEJM198311173092016

Epstein, E, Glaser, JB, Seligman, SJ, Sack, J, Martinowitz, U, Neuman, Y, Laks, J, Katznelson, D, Ramot, B, Balfour, HH, Bean, B, Laskin, OL, Ambinder, RF, Meyers, JD, Wade, JC, Zaia, JA, Aeppli, D, Kirk, LE, Segreti, AC & Keeney, RE 1983, 'Acyclovir for Immunocompromised Patients with Herpes Zoster', New England Journal of Medicine, vol. 309, no. 20, pp. 1254-1255. https://doi.org/10.1056/NEJM198311173092016

@article{9a41c8cdee85431ba85a24e244d227b8,

title = "Acyclovir for Immunocompromised Patients with Herpes Zoster",

abstract = "To the Editor: The important article by Balfour et al. offers convincing evidence of the value of acyclovir in the management of immunosuppressed patients with herpes zoster (June 16 issue).1 This is a serious and frequently fatal illness. On the other hand, it must not be forgotten that in the usual outpatient practice, where most examples of zoster are encountered, it is not a life-threatening illness. Its importance lies in the discomfort it produces and the possibility of the development of postzoster neuralgia. Therefore, the goals of therapy in this group of patients are different from those considered by Balfour.",

author = "Ervin Epstein and Glaser, {Jordan B.} and Seligman, {Stephen J.} and Joseph Sack and Uri Martinowitz and Yoram Neuman and Jossi Laks and Daniel Katznelson and Bracha Ramot and Balfour, {Henry H.} and Bonnie Bean and Laskin, {Oscar L.} and Ambinder, {Richard F.} and Meyers, {Joel D.} and Wade, {James C.} and Zaia, {John A.} and Dorothee Aeppli and Kirk, {L. Edward} and Segreti, {Anthony C.} and Keeney, {Ronald E.}",

year = "1983",

month = nov,

day = "17",

doi = "10.1056/NEJM198311173092016",

language = "English (US)",

volume = "309",

pages = "1254--1255",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "20",

}

TY - JOUR

T1 - Acyclovir for Immunocompromised Patients with Herpes Zoster

AU - Epstein, Ervin

AU - Glaser, Jordan B.

AU - Seligman, Stephen J.

AU - Sack, Joseph

AU - Martinowitz, Uri

AU - Neuman, Yoram

AU - Laks, Jossi

AU - Katznelson, Daniel

AU - Ramot, Bracha

AU - Balfour, Henry H.

AU - Bean, Bonnie

AU - Laskin, Oscar L.

AU - Ambinder, Richard F.

AU - Meyers, Joel D.

AU - Wade, James C.

AU - Zaia, John A.

AU - Aeppli, Dorothee

AU - Kirk, L. Edward

AU - Segreti, Anthony C.

AU - Keeney, Ronald E.

PY - 1983/11/17

Y1 - 1983/11/17

N2 - To the Editor: The important article by Balfour et al. offers convincing evidence of the value of acyclovir in the management of immunosuppressed patients with herpes zoster (June 16 issue).1 This is a serious and frequently fatal illness. On the other hand, it must not be forgotten that in the usual outpatient practice, where most examples of zoster are encountered, it is not a life-threatening illness. Its importance lies in the discomfort it produces and the possibility of the development of postzoster neuralgia. Therefore, the goals of therapy in this group of patients are different from those considered by Balfour.

AB - To the Editor: The important article by Balfour et al. offers convincing evidence of the value of acyclovir in the management of immunosuppressed patients with herpes zoster (June 16 issue).1 This is a serious and frequently fatal illness. On the other hand, it must not be forgotten that in the usual outpatient practice, where most examples of zoster are encountered, it is not a life-threatening illness. Its importance lies in the discomfort it produces and the possibility of the development of postzoster neuralgia. Therefore, the goals of therapy in this group of patients are different from those considered by Balfour.

UR - http://www.scopus.com/inward/record.url?scp=0021074424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021074424&partnerID=8YFLogxK

U2 - 10.1056/NEJM198311173092016

DO - 10.1056/NEJM198311173092016

M3 - Letter

C2 - 6633579

AN - SCOPUS:0021074424

SN - 0028-4793

VL - 309

SP - 1254

EP - 1255

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 20

ER -

Acyclovir for Immunocompromised Patients with Herpes Zoster

Abstract

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this